Russian Chemical Bulletin

, Volume 65, Issue 2, pp 507–512 | Cite as

New fluorine-18 labeled benzaldehydes as precursors in the synthesis of radiopharmaceuticals for positron emission tomography

  • V. V. Orlovskaja
  • O. S. Fedorova
  • E. P. Studentsov
  • A. A. Golovina
  • R. N. Krasikova
Full Articles


4,5-Bis(butoxy)-2-nitrobenzaldehyde and 4,5-bis(tert-butoxycarbonyloxy)-2-nitrobenzaldehyde, as well as their fluorine-18 labeled derivatives (the half-life of F18 is T 1/2 = 110 min) were synthesized for use as precursors in the synthesis of fluorine-18 labeled catecholamines and 6-[18F]fluoro-l-DOPA ((S)-3-[4,5-dihydroxy-2-[18F]fluorophenyl]-2-aminopropionic acid), important radiopharmaceutical agents (RPAs) for positron emission tomography. An advantageous feature of the newly obtained substituted nitrobenzaldehydes is the presence of labile protective groups which can be removed without using aggressive chemicals and severe conditions, which is of fundamental importance for automation of the RPA synthesis in modern synthesis apparatus. A high and stable radiofluorination yield achieved under the optimum fluorination conditions (Kryptofix 222 [K/K2.2.2.]+[18F], DMF, 140 °C, 10 min) using 4,5-bis(butoxy)-2-nitrobenzaldehyde as a substrate (83±6%, the number of experiments was n = 15) makes this compound a precursor of choice for the radioactive synthesis.

Key words

fluorine-18 18radiopharmaceuticals positron emission tomography substituted nitrobenzaldehydes nucleophilic radiofluorination fluorine-18 labeled aromatic amino acids 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. Eberl, T. Eriksson, O. Svedberg, Appl. Radiat. Isot., 2012, 70, 922.CrossRefGoogle Scholar
  2. 2.
    L. Cai, S. Lu, V. W. Pike, Eur. J. Org. Chem., 2008, 2853.Google Scholar
  3. 3.
    Y.-S. Ding, C.-Y. Shiue, J. S. Fowler, A. P. Wolf, A. Plenevaux, J. Fluorine Chem., 1990, 48, 189.CrossRefGoogle Scholar
  4. 4.
    M. Attina, F. Cacace, A. P. Wolf, J. Label. Compd. Radiopharm., 1983, 20, 501.CrossRefGoogle Scholar
  5. 5.
    R. Krasikova, Curr. Org. Chem., 2013, 17, 2097.CrossRefGoogle Scholar
  6. 6.
    E. S. Garnett, G. Firnau, C. Nahmias, Nature, 1983, 305, 137.CrossRefGoogle Scholar
  7. 7.
    H. Minn, S. Kauhanen, M. Seppanen, P. Nuutila, J. Nucl. Med., 2009, 50, 1915.CrossRefGoogle Scholar
  8. 8.
    M. Pretze, C. Wängler, B. Wängler, BioMed Res. Int., 2014, Article ID 674063; Doi 10.1155/2014/674063.Google Scholar
  9. 9.
    C. Lemaire, in PET studies on Amino Acid Metabolism and Protein Synthesis. Developments in Nuclear Medicine, Eds B. M. Mazoyer, W. D. Heiss, D. Comar, Springer, Dordrecht, 1993, p. 89.Google Scholar
  10. 10.
    R. N. Krasikova, O. F. Kuznetsova, O. S. Fedorova, I. K. Mosevich, V. I. Maleev, Yu. N. Belokon´, T. F. Savel´eva, A. S. Sagiyan, S. A. Dadayan, A. A. Petrosyan, Radiochem. (Engl. Transl.), 2007, 49, 512 [Radiokhimiya, 2007, 49, 449].Google Scholar
  11. 11.
    C. Lemaire, S. Gillet, S. Guillouet, A. Plenevaux, J. Aerts, A. Luxen, Eur. J. Org. Chem., 2004, 2899.Google Scholar
  12. 12.
    R. N. Krasikova, V. V. Zaitsev, S. M. Ametamey, O. F. Kuznetsova, O. S. Fedorova, I. K. Mosevich, Yu. N. Belokon, Р. Vyskocil, S. V. Shatik, M. Nader, P. A. Schubiger, J. Nucl. Med. Biol., 2004, 31, 597.CrossRefGoogle Scholar
  13. 13.
    C. Libert, X. Franci, A. R. Plenevaux, T. Ooi, K. Maruoka, A. J. Luxen, C. F. Lemaire, J. Nucl. Med., 2013, 54, 1154.CrossRefGoogle Scholar
  14. 14.
    A. Horti, D. E. Redmond, R. Soufer, J. Label. Compd. Radiopharm., 1995, 36, 409.CrossRefGoogle Scholar
  15. 15.
    С. Lemaire, P. Damhaut, A. Plenevaux, D. Comar, J. Nucl. Med., 1994, 35, 1996.Google Scholar
  16. 16.
    C. Lemaire, A. Plenevaux, R. Cantineau, Appl. Radiat. Isot., 1993, 44, 737.CrossRefGoogle Scholar
  17. 17.
    B. Shen, W. Ehrlichmann, M. Uebele, H.-J. Machulla, G. Reischl, Appl. Radiat. Isot., 2009, 67, 1650.CrossRefGoogle Scholar
  18. 18.
    L. Zhang, G. Tang, D. Yin, X. Tang, Y. Wang, Appl. Radiat. Isot., 2002, 57, 145.CrossRefGoogle Scholar
  19. 19.
    R. Krasikova, V. Orlovskaja, O. Fedorova, V. Maleev, T. Savelieva, Yu. Belokon, Quart. J. Nucl. Med. Mol. Imaging, 2014, 58, 63.Google Scholar
  20. 20.
    O. S. Fedorova, V. V. Orlovskaya, V. I. Maleev, Yu. N. Belokon´, T. F. Savel´eva, Ch. V. Chang, Ch. L. Chen, R. Sh. Liu, R. N. Krasikova, Russ. Chem. Bull. (Int. Ed.), 2014, 63, 1169 [Izv. Akad. Nauk, Ser. Khim., 2014, 1169].CrossRefGoogle Scholar
  21. 21.
    Protective Groups in Organic Chemistry, Ed. J. F. W. McOmie, Plenum Press, New York, 1973.Google Scholar
  22. 22.
    B. P. Murphy, J. Org. Chem., 1985, 50, 5873.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • V. V. Orlovskaja
    • 1
  • O. S. Fedorova
    • 1
    • 3
  • E. P. Studentsov
    • 2
  • A. A. Golovina
    • 2
  • R. N. Krasikova
    • 1
    • 3
  1. 1.N. P. Bechtereva Institute of Human BrainRussian Academy of SciencesSaint PetersburgRussian Federation
  2. 2.Saint Petersburg State Technological Institute (Technical University)Saint PetersburgRussian Federation
  3. 3.Department of ChemistrySaint Petersburg State UniversitySaint PetersburgRussian Federation

Personalised recommendations